Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is well-positioned to potentially disrupt the current market for schizophrenia treatment with its promising drug, roluperidone, which addresses the unmet need for a treatment for negative symptoms. With strong patent protection and positive clinical trial results, the company has the potential to become a major player in the biopharmaceutical industry. Investors should keep a close eye on the ongoing Phase 3 trial and the FDA's response to the potential approval of roluperidone.

Bears say

Minerva Neurosciences is expected to experience negative financial and legal impacts due to the unimpressive results of its confirmatory Phase 3 study for the drug Roluperidone, which has the potential to be the first approved therapy for negative symptoms in schizophrenia patients. The company's recent financing activities demonstrate its need for additional capital, possibly indicating a lack of confidence in the drug's future success. However, its post-hoc analysis showed promising results for both doses, supported by highly significant responder rates, which could lead to a potential approval in the future.

Minerva Neurosciences (NERV) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Hold based on their latest research and market trends.

According to 2 analysts, Minerva Neurosciences (NERV) has a Hold consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.